Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Tumour response endpoints in the BA1112 rat sarcoma. Br J Cancer Suppl 1980 Apr;4:271-4

Date

04/01/1980

Pubmed ID

6932936

Pubmed Central ID

PMC2149194

Scopus ID

2-s2.0-0018830227 (requires institutional sign-in at Scopus site)   15 Citations

Abstract

The rat rhabdomyosarcoma BA1112 has a number of features which make it a useful model for the study of tumour response to radiation therapy. It is a transplantable tumour, isologous to an inbred line of WAG/Rij rats and it elicits no demonstrable host immune response. The tumour grows locally at the implantation site and rarely metastasizes. It is known to contain hypoxic cells which reoxygenate during a prolonged course of fractionated radiation therapy. The growth and radiation response characteristics of the tumour have remained stable for over 15 years. A newly developed in vitro assay for tumour cell clonogenicity greatly facilitates the measurement of radiation dose-response curves and the monitoring of cell response following in vivo treatment. The in vivo response of the tumour to fractionated radiation therapy is analysed in terms of cellular response, reoxygenation and cell proliferation.

Author List

Martin DF, Moulder JE, Fischer JJ



MESH terms used to index this publication - Major topics in bold

Animals
Cell Survival
Culture Techniques
Disease Models, Animal
Dose-Response Relationship, Radiation
Oxygen
Rats
Rhabdomyosarcoma
Sarcoma, Experimental
Time Factors